Report cover image

Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 16, 2024
Length 198 Pages
SKU # IRE18418354

Description

Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2024-2030


The Anterior Uveitis Treatment Market size was estimated at USD 255.63 million in 2023 and expected to reach USD 277.28 million in 2024, at a CAGR 8.56% to reach USD 454.31 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anterior Uveitis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anterior Uveitis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anterior Uveitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aciont Inc., Ajanta Pharma Ltd, Aldeyra Therapeutics, Inc., Alimera Sciences Inc., American Academy of Ophthalmology, Amgen Inc., Bausch & Lomb Incorporated, Cipla Ltd., Clearside Biomedical, Inc., Enzo Biochem Inc., Eyegate Pharmaceuticals, Inc, HanAll Biopharma, Kiora Pharmaceuticals, Inc., L V PRASAD EYE INSTITUTE, Lux Biosciences, Inc., Novartis AG, Oculis SA, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Sirion Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., Tarsier Pharma Ltd, and Xoma Corporation.

Market Segmentation & Coverage

This research report categorizes the Anterior Uveitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type

Anti-Tumor Necrosis Factor Agents
  • Corticosteroids
  • Cycloplegic Agents
  • Immunosuppressants
  • Distribution Channel

    Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Anterior Uveitis Treatment Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anterior Uveitis Treatment Market?
    3. What are the technology trends and regulatory frameworks in the Anterior Uveitis Treatment Market?
    4. What is the market share of the leading vendors in the Anterior Uveitis Treatment Market?
    5. Which modes and strategic moves are suitable for entering the Anterior Uveitis Treatment Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    198 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Anterior Uveitis Treatment Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rising prevalence of eye infections
    5.1.1.2. Growing demand for drugs such as corticosteroids and anti-inflammatory medications
    5.1.1.3. Growing awareness about the uveitis treatment
    5.1.2. Restraints
    5.1.2.1. High cost and limited awareness about the medications
    5.1.3. Opportunities
    5.1.3.1. Development of research companies on biological drugs
    5.1.3.2. Rising expenditure on the research and development of novel drugs and treatments for Uveitis
    5.1.4. Challenges
    5.1.4.1. Side effect associated with corticosteroid treatment
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Anterior Uveitis Treatment Market, by Treatment Type
    6.1. Introduction
    6.2. Anti-Tumor Necrosis Factor Agents
    6.3. Corticosteroids
    6.4. Cycloplegic Agents
    6.5. Immunosuppressants
    7. Anterior Uveitis Treatment Market, by Distribution Channel
    7.1. Introduction
    7.2. Hospital Pharmacies
    7.3. Online Pharmacies
    7.4. Retail Pharmacies
    8. Americas Anterior Uveitis Treatment Market
    8.1. Introduction
    8.2. Argentina
    8.3. Brazil
    8.4. Canada
    8.5. Mexico
    8.6. United States
    9. Asia-Pacific Anterior Uveitis Treatment Market
    9.1. Introduction
    9.2. Australia
    9.3. China
    9.4. India
    9.5. Indonesia
    9.6. Japan
    9.7. Malaysia
    9.8. Philippines
    9.9. Singapore
    9.10. South Korea
    9.11. Taiwan
    9.12. Thailand
    9.13. Vietnam
    10. Europe, Middle East & Africa Anterior Uveitis Treatment Market
    10.1. Introduction
    10.2. Denmark
    10.3. Egypt
    10.4. Finland
    10.5. France
    10.6. Germany
    10.7. Israel
    10.8. Italy
    10.9. Netherlands
    10.10. Nigeria
    10.11. Norway
    10.12. Poland
    10.13. Qatar
    10.14. Russia
    10.15. Saudi Arabia
    10.16. South Africa
    10.17. Spain
    10.18. Sweden
    10.19. Switzerland
    10.20. Turkey
    10.21. United Arab Emirates
    10.22. United Kingdom
    11. Competitive Landscape
    11.1. FPNV Positioning Matrix
    11.2. Market Share Analysis, By Key Player
    11.3. Competitive Scenario Analysis, By Key Player
    12. Competitive Portfolio
    12.1. Key Company Profiles
    12.1.1. AbbVie Inc.
    12.1.2. Aciont Inc.
    12.1.3. Ajanta Pharma Ltd
    12.1.4. Aldeyra Therapeutics, Inc.
    12.1.5. Alimera Sciences Inc.
    12.1.6. American Academy of Ophthalmology
    12.1.7. Amgen Inc.
    12.1.8. Bausch & Lomb Incorporated
    12.1.9. Cipla Ltd.
    12.1.10. Clearside Biomedical, Inc.
    12.1.11. Enzo Biochem Inc.
    12.1.12. Eyegate Pharmaceuticals, Inc
    12.1.13. HanAll Biopharma
    12.1.14. Kiora Pharmaceuticals, Inc.
    12.1.15. L V PRASAD EYE INSTITUTE
    12.1.16. Lux Biosciences, Inc.
    12.1.17. Novartis AG
    12.1.18. Oculis SA
    12.1.19. Pfizer Inc.
    12.1.20. Regeneron Pharmaceuticals, Inc.
    12.1.21. Santen Pharmaceutical Co., Ltd.
    12.1.22. Sirion Therapeutics, Inc.
    12.1.23. Sun Pharmaceutical Industries Ltd.
    12.1.24. Tarsier Pharma Ltd
    12.1.25. Xoma Corporation
    12.2. Key Product Portfolio
    13. Appendix
    13.1. Discussion Guide
    13.2. License & Pricing
    FIGURE 1. ANTERIOR UVEITIS TREATMENT MARKET RESEARCH PROCESS
    FIGURE 2. ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTERIOR UVEITIS TREATMENT MARKET DYNAMICS
    FIGURE 7. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
    FIGURE 8. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
    FIGURE 10. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 12. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 14. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ANTERIOR UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 20. ANTERIOR UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us